A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity

IF 7.2 2区医学

Oncoimmunology Pub Date : 2024-02-16 DOI:10.1080/2162402x.2024.2316945

Diana I. Albu, Benjamin J. Wolf, Yan Qin, Xianzhe Wang, Amy Daniel Ulumben, Mei Su, Vivian Li, Eirene Ding, Jose Angel Gonzalo, Jason Kong, Ruturaj Jadhav, Nelly Kuklin, Alberto Visintin, Bing Gong, Thomas J. Schuetz

引用次数: 0

Abstract

Combinatorial strategies, such as targeting different immune checkpoint receptors, hold promise to increase the breadth and duration of the response to cancer therapy. Here we describe the preclini...

查看原文本刊更多论文

一种双特异性抗 PD-1 和 PD-L1 抗体可诱导 PD-1 分裂并增强抗肿瘤活性

针对不同免疫检查点受体的组合策略有望增加癌症治疗反应的广度和持续时间。在这里，我们描述了针对不同免疫检查点受体的预...

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncoimmunology ONCOLOGY-IMMUNOLOGY

CiteScore

12.80

自引率

2.80%

发文量

276

期刊介绍： Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.